Triple
T9807398
| Position | Surface form | Disambiguated ID | Type / Status |
|---|---|---|---|
| Subject | programmed death-ligand 1 |
E238185
|
entity |
| Predicate | targetOfDrug |
P37016
|
FINISHED |
| Object | pembrolizumab |
E468955
|
NE FINISHED |
How this triple was built (2 steps)
Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.
NER
Named-entity recognition
gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: pembrolizumab | Statement: [programmed death-ligand 1, targetOfDrug, pembrolizumab]
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: pembrolizumab Context triple: [programmed death-ligand 1, targetOfDrug, pembrolizumab]
-
A.
Keytruda
chosen
Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.
-
B.
Libtayo
Libtayo is a monoclonal antibody immunotherapy drug used primarily to treat certain types of advanced skin and lung cancers by targeting the PD-1 pathway.
-
C.
pertuzumab
Pertuzumab is a monoclonal antibody used in targeted therapy for HER2-positive breast cancer, often administered alongside trastuzumab and chemotherapy.
-
D.
Imfinzi
Imfinzi is a prescription immunotherapy drug (durvalumab) developed by AstraZeneca, primarily used to treat certain types of lung and bladder cancers by helping the immune system attack cancer cells.
-
E.
Tecentriq
Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
- F. None of above.
- G. Unsure - the case is ambiguous/there is not enough information to decide.
Provenance (3 batches)
The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.
| Step | Stage | Batch ID | Status | When |
|---|---|---|---|---|
| creating | Elicitation | batch_69ca84defac48190abc1148804f184c1 |
completed | March 30, 2026, 2:12 p.m. |
| NER | Named-entity recognition | batch_69cdab7ddaac8190a5584a5c863fbaa3 |
completed | April 1, 2026, 11:34 p.m. |
| NED1 | Entity disambiguation (via context triple) | batch_69d1cc57119881909616d835def02fc9 |
completed | April 5, 2026, 2:43 a.m. |
Created at: March 30, 2026, 8:29 p.m.